Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: A systematic review and meta-analysis - 27/05/16

Doi : 10.1016/j.clinre.2015.07.008

Qi-Wen Chen ^a,^b,^{^{1
Q.W. Chen, H.F. Ying and S. Gao contributed equally to this work and should be considered as co-first authors.}}, Hai-Feng Ying ^c,^{^{1
Q.W. Chen, H.F. Ying and S. Gao contributed equally to this work and should be considered as co-first authors.}}, Song Gao ^a,^{^{1
Q.W. Chen, H.F. Ying and S. Gao contributed equally to this work and should be considered as co-first authors.}}, Ye-Hua Shen ^a, Zhi-Qiang Meng ^a, Hao Chen ^a, Zhen Chen ^a,^⁎ , Wen-Jing Teng ^d
^a Fudan University Shanghai, Cancer Center, Department of Integrated Oncology, 200032 Shanghai, PR China
^b Fudan University, Institute of Clinical Epidemiology, School of Public Health, Key Laboratory of Public Health Safety of Ministry of Education, 200032 Shanghai, PR China
^c Shanghai Jiaotong University, School of Medicine, Ruijin Hospital, Department of Traditional Chinese Medicine, 200025 Shanghai, PR China
^d University of Traditional Chinese Medicine, Post Graduate School of Shandong, Weifang Hospital of Traditional Chinese Medicine, Cancer Treatment Center, First Department, 250355 Jinan, Shandong Province, PR China

^⁎Corresponding author.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

pages	6
Iconographies	3
Vidéos	0
Autres	0

Summary

Background

To determine whether the use of radiofrequency ablation (RFA) plus transcatheter arterial chemoembolization (TACE) is more effective than the use of RFA alone for patients with hepatocellular carcinoma (HCC).

Methods

A computer-based search was performed. Randomised trials comparing RFA plus TACE and RFA alone for treatment of HCC were included in this meta-analysis. The outcome of interest for our analysis was survival (recurrence-free survival and overall survival).

Results

Eight trials with 648 patients were eligible for this meta-analysis. Our pooled results suggest that RFA plus TACE is associated with a significant advantage in recurrence-free survival (RFS) (HR=0.58; 95% CI=0.42–0.80, P=0.001), and overall survival (OS) (HR=0.60; 95% CI=0.47–0.76, P<0.001).

Conclusion

TACE combined with RFA was more effective than RFA alone, especially for treatment for intermediate and large-size hepatic tumours or younger patients with HCC.

Le texte complet de cet article est disponible en PDF.

Plan

Introduction

Methods

Search strategy

Inclusion and exclusion criteria

Statistical analysis

Results

Description of trials

Meta-analysis

Publication bias

Discussion

Disclosure of interest

Export

Vol 40 - N° 3

P. 309-314 - juin 2016 Retour au numéro

Article précédent

The effect of peginterferon alpha-2a vs. interferon alpha-2a on intrahepatic covalently closed circular DNA in HBeAg-positive chronic hepatitis B patients
Sufen Liu, Huanwei Zheng, Yan Huang, Bingshun Li, Zhenghong Dong

| Article suivant

Clinical outcomes and risk factors of hepatocellular carcinoma treated by liver transplantation: A multi-centre comparison of living donor and deceased donor transplantation
Zhenhua Hu, Ze Qian, Jian Wu, Jie Zhou, Min Zhang, Lin Zhou, Shusen Zheng

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: A systematic review and meta-analysis - 27/05/16

Summary

Background

Methods

Results

Conclusion

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL